NERV

Minerva is a clinical-stage company with zero revenue in every year of its history and a business the 10-K says is "highly dependent on the success of roluperidone." That is the definition of unknowable, binary risk: the entire equity value rests on one schizophrenia candidate that must still clear FDA review, and the filing openly warns it may "never achieve or maintain profitability" and "will require additional capital" that may not be available "on acceptable terms, or at all." There is nothing in the numbers a fundamental investor can underwrite — no sales, no margins, no returns on capital to reward.

The balance sheet is the disqualifier. FY2025 stockholders' equity is -$141M against $234M of total liabilities on just $98.0M of assets (liabilities/equity of -1.66x), and the accumulated deficit has ballooned to -$689M. The $293M net loss dwarfs the -$15.1M operating loss, meaning the bulk is non-operating/non-cash (consistent with derivative or warrant revaluation), but the outcome is still a company that owes far more than it owns. The one bright spot — $82.3M cash and current assets of $83.1M against only $2.29M current liabilities — buys runway but does not offset a deeply negative book value.